Ardelyx (ARDX) says FDA has identified deficiencies that preclude discussion of labeling and post-marketing requirements/commitments for Tenapanor at this time
Go back to Ardelyx (ARDX) says FDA has identified deficiencies that preclude discussion of labeling and post-marketing requirements/commitments for Tenapanor at this time| Oppenheimer Rising Dividends Fund, Inc. Class A (NASDAQ: ARDX) | Delayed: 6.37 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $6.37 | 52 Week High | $20.98 | |||
| Open | $6.37 | 52 Week Low | $6.36 | |||
| Day High | $6.37 | P/E | N/A | |||
| Day Low | $6.37 | EPS | $0.00 | |||
| Volume | 244 | |||||
